Biotech-Focused Fund Adds Million: Immunome Bet Surges
A leading biotech-focused fund just boosted its Immunome position by a material amount as the stock surged. This arti...
Not all retirees benefit equally from Target Date Funds. This guide points out scenarios and preferences where avoidance may be wise.
27,346 articlesA leading biotech-focused fund just boosted its Immunome position by a material amount as the stock surged. This arti...
A Polymarket admin wallet on the Polygon network was compromised, with investigators estimating losses above $600,000...
Two separate California cases show how funds meant for students can be diverted into luxury purchases. This article e...
Is it time to move on from Cardano? This article explains three concrete reasons to consider selling Cardano today an...
Netflix has transformed how we watch TV, but investors are asking if the stock can reach $200. This article breaks do...
Markets are sizzling, but does that change the wisdom of simply following the S&P 500? This guide breaks down the rea...
A major biotech fund has increased its stake in Scholar Rock, increasing exposure to a platform that targets protein ...
When a top banker speaks, markets listen. These words from Goldman signal a continuing market flywheel that could sha...
Kick off your week with 10 Sunday reads that translate heavy market chatter into actionable investing moves. Each ite...
A little-known rule could turn leftover 529 funds into a tax-free retirement windfall. If a 62-year-old with $35,000 ...
The U.S. Department of Housing and Urban Development has halted new funding to VIHFA while investigators probe allega...
Global crypto funds posted inflows for the sixth straight week, totaling $858 million, driven by U.S. listed products...